Drug and Therapeutics Committee – Minutes –Confirmed

Date / Time	Thursday 13th July 2017
Venue	The Board Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs Amy Mathie, Pharmacy Admin Assistant (AM)
Quorate: Yes / No	Yes

Attendance

Prof M Lind, Vice Chair, Professor of Oncology
Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SPG)
Dr O Ogunbambi, Consultant Rheumatologist
Dr F Umerah, Consultant Anaesthetist
Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics
Mrs E Lyle, Locality Pharmacist, Medicines Management, Hull NECS (deputy for KMcC)

Apologies

Mr P O'Brien, Deputy Chief Pharmacist
Dr H Klonin, Consultant Paediatrician
Mrs Sue Phillips, Lay Representative
Mr K McCorry, Medicines Management, East Riding
Mr R Kapur, Vascular Surgeon Sue Green
Mrs Susan Greene, Senior Pharmacy Technician (SG)

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2017.07.01	**Apologies**	As Above.					7/17
2017.07.02	**Declarations of Interest**	None.					7/17
2017.07.03	**Minutes of the previous meeting**	The minutes were accepted as a true record.					7/17
2017.07.04	**Action Tracker**	**Bisphosphonates as supportive therapy for Breast Cancer** ML to write local protocol – then send to SG for discussion at HERPC. ML said there is a meeting due to take place on 14/07/17 and this will be discussed - ongoing. **Fluticasone Furoate and Vilanterol (Relvar Ellipta)** POB to discuss and clarify commissioning DOT with respiratory service manager. Prof Morice reported that Relvar was working well and the respiratory team wanted to continue patients who were well controlled on it. This would mean changing status from Red to Amber or Blue – to be discussed at HERPC. **Paediatric Growth Hormone** DC was to invite Chris Wood to HERPC to discuss further. However, DC felt this action had been superseded, as Lisa Pearce, Paediatrics Service Manager, was writing a paper on the impact of the proposed change. This would be discussed within the Trust and later at HERPC. **Obeticholic Acid (Ocaliva) Capsules** - Dr Lynsey Corless JM tried to clarify commissioning arrangements with POB. Due to the general election, NHSE had put issuing their position on hold. **NICE Guidance April 2017**	Ongoing. Ongoing. Agenda status for HERPC. Action superseded. Ongoing.	Await feedback from meeting. POB to ask service manager SG to agenda at HERPC No further action at D&TC POB to clarify commissioning arrangements	ML POB SG POB	5/17 7/17 7/17 7/17	7/17

		Ixekizumab for treating moderate to severe plaque psoriasis Non-formulary, application needed. AM had written to Dr Zaman.	Action Complete.				7/17
		D&T Attendance 16-17 Report accepted with the amendments: K McCorry – April & July/16 – Sent deputy (EL) – change to orange. Dr A Samson – name to be corrected. State "started April/17". Dr E Williamson – to be added, prior to Dr Samson, with leaving date.	SG to amend report	Ongoing	SG	7/17	
		D&T Product Requests 16-17 Report accepted with the amendments: Relvar should be RED, making number red 32, number green 1.	SG to amend report	Ongoing	SG	7/17	
		Levofloxacin – reinstatement on formulary SG to put back on formulary as RED & ALERT drug. KM to provide an analysis of any current use in Primary care.	SG to update KMcC to check usage	Ongoing Ongoing	SG KMcC	7/17 7/17	
		Desmopressin Acetate Proposed as RED Drug for this formulation/use. ML had written to Mr Klaus about monitoring and audit of use at 6 months.	Action Complete.				7/17
		Imuderm emollient ML had written to Dr Zaman regarding which product this would replace.	Action Complete.				7/17
		Anticoagulation Prescribing Guidance POB had liaised with Yvonne Holloway to share the poster with medical staff.	Action Complete.				7/17
		Any other Business Akynzeo & Ibrance - ML had liaised with Oncology colleagues. These products were on this agenda	Action Complete.				7/17
2017.07.05	**New Product Requests**	**Fiasp Insulin (Fast-Acting Insulin Aspart) – Dr B. Allan** This is a new fast acting mealtime insulin, which gave better glycaemic control without excessive hypoglycaemia episodes. The FlexTouch pen has an improved mechanism, compared to the Novorapid Flexpen.	Approved.	AM to write to applicants SG to update formulary	AM SG	8/17 8/17	

		Akynzeo (Netupitant/Palonosetron) Capsules - Dr M Butt Dr Patmore had originally signed the new product request form on 21/06/2016. The form had never been sent to the Committee, due to discussions within Oncology/CS Health Group about the pricing & placement of the product. The committee had recently received the request form, but Prof Morice felt it was prudent to confirm that this was now to be processed, as it was a year later. Correspondence from Dr Patmore on 10/072017 stated that he was not happy to support the application. This was because it would involve changing Aria protocols over, but soon generic aprepitant would be available and if the Trust were to make savings the protocols would all require changing back.	Not discussed, at Medical Director's request.	Prof Lind to speak with Dr Butt to explain outcome	ML	8/17	
		Palbociclib (Ibrance) Capsules – Dr S Upadhyay This application was approved. Pfizer had launched a free of charge access programme on 18/04/2017, to close 6 weeks after NICE issue their FAD or on 30/09/2017, whichever is sooner. Patients on the drug via this scheme would continue free of charge for as long as they derive benefit.	Approved, but review formulary status when NICE is published.				
		Octenidine (Octenisan) antimicrobial wash lotion 150ml – Infection Control Team The Trust currently uses Skinsan Foam (triclosan 2%) for MRSA eradication. Correspondence from the IC team indicated the manufacturer of Skinsan are discontinuing this product and launching Skinsan N scrub, containing chlorhexidine. This would be used differently, by being left on the skin, rather than triclosan that is washed off. Octenidene had previously been approved by D&TC as a nasal gel for MRSA eradication, when there were supply problems with Bactroban Nasal. There was further discussion about use in children & neonates, where the company do not recommend use under 3 years of age. This was due to the Cosmetic Products Regulation 1223/2009/EC that requires a safety assessment assuming regular life-time use. It is known that octenidine is not absorbed from skin, mucous membranes and wounds. Other Trusts e.g. Leeds and GOSH are also using octenidine for under 3 years. The committee approved this change to Octenidene wash lotion for all ages.	Approved.	SPG to liaise with IC team regarding posters for wards and a launch Trust global e-mail	SPG	8/17	
		Glecaprevir/Pibrentasvir – Lorraine Cullen This combination for Chronic hepatitis C was approved for FOC use, in line with NHSE position statement and the MHRA EAMS.	Approved.				

2017.07.06	**NICE Guidance**	**June 2017**					
		Air Pollution: Outdoor quality and health https://nice.org.uk/guidance/ng70	Noted	No further Action			7/17
		Brentuximab vedotin for treating CD30- positive Hodgkin lymphoma https://www.nice.org.uk/guidance/ta446	Currently on CDF list.	AM to write to Haematology for new product request	AM	8/17	
		Pembrolizumab for untreated PD-L1-Postive metastatic non-small-cell lung cancer – adults https://ww.nice.org.uk/guidance/ta447	Listed on formulary as chairs approval until requested.	ML to complete a new product request form	ML	8/17	
		Etelcalcetide for treating secondary hyperparathyroidism https://www.nice.org.uk/guidance/ta449	Non-formulary	AM to write to Renal for new product request	AM	8/17	7/17
		Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease https://www.nice.org.uk/guidance/ta449	Everolimus listed on CDF list and on chairs approval. Sunitinib is on the formulary.	SG to add everolimus “as per NICE guidance” on formulary No further Action	SG	8/17	
		Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia https://www.nice.org.uk/guidance/ta450	Non-formulary.	AM to write to Haematology for new product request	AM	8/17	
		Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia https://www.nice.org.uk/guidance/ta451	Ponatinib listed on CDF list.	AM to write to Haematology for new product request	AM	8/17	

		Spondyloarthritis in over 16s: diagnosis and management https://www.nice.org.uk/guidance/ng65 Head Injury: assessment and early management https://wwwnice.org.uk/guidance/cg176 Obesity: Working with local communities https://www.nice.org.uk/guidance/ph42	Review noted. Review noted. Review noted.	No further Action No further Action No Further Action			7/17 7/17 7/17
2017.07.07	**MHRA Drug Safety update**	**June 2017** • Denosumab Reports of osteonecrosis of the external auditory canal. • Brimonidine gel – non-formulary • Pseudoephedrine & ephedrine – noted • e-cigarettes & refill containers (e-liquids) - noted	AM to write to Haematology	AM to write to Dr James Bailey	AM	8/17	
2017.07.08	**Minutes from the Safe Medication Practice Committee**	None.					7/17
2017.07.09	**Minutes from the Hull and East Riding Prescribing Committee**	None.					7/17
2017.07.10	**Correspondence received**	**Response letter from Dr Ming re- Brivacetam** Dr Ming had written to explain that brivacetam would only be used for patients with refractory epilepsy who have failed on all other anti-epileptics. Patients would be initiated and monitored by the specialist Neurology doctors and epilepsy specialist nurses. It was thought this was fine and brivacetam could be added to the formulary. **SSC1758 - Early Access to Medicines Scheme – Idebenone as treatment for slowing the decline of respiratory function in patients with Duchenne Muscular Dystrophy (DMD) from the age of 10 years who are currently not taking glucocorticoids** It was felt that if this agent was required, then a new product request would need to be submitted to D&TC.	Dr Ming's plan accepted and brivacetam approved for specialist use. AM to write to Dr Greenstone to ask if he wishes to submit a new product request for the drug.	AM to write to Dr Greenstone	AM	8/17	7/17

2017.07.11	**Chairs Approvals**	Campath (Alemtuzumab)- Kidney transplant recipient steroid resistant rejection of transplant- Dr T Jorna	Noted.	No further action			7/17
2017.07.12	**Issues to escalate to Operational Quality Committee**	None.					7/17
2017.07.13	**Any Other Business**	Remifentanil injection – currently not available from Pharmacy for ICU sedation and use in theatres, due to a nationwide shortage. Anaesthetics will use alternative opioids, e.g. alfentanil for ICU sedation, as was used in the past. Dr Umerah raised the issue of using dexmedetomidine in theatre, as a way of sparing the amount of opioid used. D&TC had previously approved this agent for use on ICU as a sedative, as per the product licence. It was not licenced for peri-operative use in day surgery theatres. Prof Morice suggested Dr Umerah sends him any evidence of dexmedetomidine use in this way to review. SPG had circulated the letter from Dr Barlow regarding the reinstatement of levofloxacin on the formulary, as promised.	Paul to update the committee if the situation changes. Dexmedetom-idine not currently approved for use in theatre. Noted	 FU to send AM any evidence for use in this way No further action	 FU	 8/17	7/17 7/17
2017.07 14	**Date and Time of Next Meeting**	**Date – Thursday 10th August 2017** **Time – 8.15am-9.30am** **Venue – Board Room, Alderson House, HRI**					